Monica Facco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7229025/publications.pdf

Version: 2024-02-01

136950 123424 4,184 112 32 61 citations h-index g-index papers 113 113 113 5990 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	3.5	31
2	Identification of novel STAT5B mutations and characterization of $TCR\hat{I}^2$ signatures in CD4+ T-cell large granular lymphocyte leukemia. Blood Cancer Journal, 2022, 12, 31.	6.2	15
3	Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience. Leukemia, 2022, 36, 1947-1950.	7.2	9
4	Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nature Communications, 2022, 13, .	12.8	7
5	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	1.4	72
6	M2 macrophages as resolvers of crystal-induced inflammation. Rheumatology, 2021, 60, 2480-2483.	1.9	2
7	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 5453.	3.7	6
8	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia, 2020, 34, 1116-1124.	7.2	49
9	<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p> . OncoTargets and Therapy, 2020, Volume 13, 9679-9688.	2.0	19
10	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology, 2020, 38, 823-826.	1.7	16
11	Vitamin D Prevents Pancreatic Cancer-Induced Apoptosis Signaling of Inflammatory Cells. Biomolecules, 2020, 10, 1055.	4.0	7
12	Identification of a <i>miR-146b</i> -Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica, 2020, 105, 1351-1360.	3 . 5	28
13	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. Blood Cancer Journal, 2020, 10, 42.	6.2	22
14	Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?. Frontiers in Oncology, 2020, 10, 613570.	2.8	3
15	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood, 2020, 136, 33-34.	1.4	1
16	BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. British Journal of Haematology, 2019, 185, 193-197.	2.5	24
17	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. British Journal of Cancer, 2019, 121, 150-156.	6.4	31
18	HSP70/HSF1 axis, regulated <i>via</i> a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	5.1	32

#	Article	IF	CITATIONS
19	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 678-685.e4.	0.4	25
20	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 2019, 11, 1939.	3.7	39
21	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. Leukemia, 2019, 33, 1148-1160.	7.2	25
22	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer Journal, 2018, 8, 51.	6.2	20
23	Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia. Oncotarget, 2018, 9, 32219-32231.	1.8	6
24	Role of <i>miR-15a/miR-16-1</i> and the <i>TP53</i> axis in regulating telomerase expression in chronic lymphocytic leukemia. Haematologica, 2017, 102, e253-e256.	3.5	13
25	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2017, 178, 81-93.	2.5	25
26	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	7.0	27
27	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. European Journal of Cancer, 2017, 72, 103-111.	2.8	29
28	Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of <i>SF3B1</i> gene refines prognosis in treatment-naÃ-ve chronic lymphocytic leukemia. Haematologica, 2017, 102, e144-e147.	3.5	4
29	Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells. Haematologica, 2017, 102, 1401-1412.	3.5	23
30	$\mbox{\sc i}\mbox{\sc STAT3}\mbox{\sc /i}\mbox{\sc mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.}$	1.8	67
31	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget, 2017, 8, 110727-110731.	1.8	23
32	Inhibition of JAK2/STAT3 Pathway Leads to Apoptosis in Chronic Lymphocytic Leukemia Cells. Blood, 2016, 128, 2023-2023.	1.4	2
33	Epidemiology and Risk Factors of Invasive Fungal Infections Among 795 Patients with Chronic Lymphocytic Leukemia from the Padua University. Blood, 2016, 128, 2527-2527.	1.4	6
34	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	1.4	1
35	Evaluation of Integrated CLL Scoring System (ICSS) in 420 Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 5563-5563.	1.4	1
36	Cortactin Is a New Player in Aggressiveness and Diffusion of Chronic Lymphocytic Leukaemia. Blood, 2016, 128, 4353-4353.	1.4	1

#	Article	IF	Citations
37	HSP70-HSF1 Interplays Has a Role in the Pathogenesis of Chronic Lymphocytic Leukemia and Is a Druggable Target. Blood, 2016, 128, 4368-4368.	1.4	O
38	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood, 2015, 125, 856-859.	1.4	70
39	Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood, 2015, 125, 3747-3755.	1.4	40
40	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	1.8	39
41	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.4	26
42	Reduced levels of circulating progenitor cells in juvenile idiopathic arthritis are counteracted by anti TNF- \hat{l} ± therapy. BMC Musculoskeletal Disorders, 2015, 16, 103.	1.9	11
43	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
44	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	2.2	36
45	Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells. Blood, 2015, 126, 3876-3876.	1.4	1
46	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	1.4	0
47	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. Haematologica, 2014, 99, 881-887.	3.5	32
48	Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and <scp>L</scp> yn inhibition by nocodazole. British Journal of Haematology, 2014, 165, 659-672.	2.5	26
49	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematology,the, 2014, 1, e74-e84.	4.6	93
50	JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	2.9	65
51	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	3.5	21
52	Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. Journal of Hypertension, 2014, 32, 193-199.	0.5	17
53	Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica, 2014, 99, 1069-1077.	3.5	32
54	Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. Blood, 2014, 124, 1969-1969.	1.4	0

#	Article	IF	Citations
55	Expression of FAK and Its Involvement in the Progression of B-Cell Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3309-3309.	1.4	0
56	NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy. Journal of the Neurological Sciences, 2013, 331, 86-89.	0.6	4
57	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
58	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 2013, 121, 3843-3854.	1.4	85
59	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	2.5	44
60	T Large Granular Lymphocytes Leukemia (T-LGLL) and Natural Killer Chronic Lymphoproliferative Disorder (NK-CLPD): Two Diseases With a Common Etiopathogenetic Mechanism?. Blood, 2013, 122, 2612-2612.	1.4	0
61	LGL Disorders: From An Inflammatory-Mediated To a Self-Maintaining Proliferation. Blood, 2013, 122, 4889-4889.	1.4	0
62	HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen. PLoS ONE, 2012, 7, e39902.	2.5	29
63	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica, 2012, 97, 56-63.	3.5	47
64	Increased Survival and Migration of CLL B-Cells in the Presence of Marrow Mesenchymal Stromal Cells: Novel Findings for Microenvironment-Targeted Therapies. Blood, 2012, 120, 4571-4571.	1.4	5
65	CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. Clinical and Experimental Rheumatology, 2012, 30, S71-5.	0.8	10
66	Pancreatic Cancer Alters Human CD4+ T Lymphocyte Function. Pancreas, 2011, 40, 1131-1137.	1.1	19
67	Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax, 2011, 66, 144-150.	5.6	247
68	Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertension Research, 2011, 34, 1017-1022.	2.7	22
69	Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia. Blood, 2011, 118, 1375-1375.	1.4	0
70	Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes. Haematologica, 2010, 95, 1722-1729.	3.5	24
71	ZAPâ€₹0 expression is associated with increased risk of autoimmune cytopenias in CLL patients. American Journal of Hematology, 2010, 85, 494-498.	4.1	31
72	3-(2,4-Dichlorophenyl)-4-(1-methyl-1 <i>H</i> -indol-3-yl)-1 <i>H</i> -pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 785-794.	2.5	36

#	Article	IF	CITATIONS
73	CXCR6-CXCL16 interaction in the pathogenesis of Juvenile Idiopathic Arthritis. Clinical Immunology, 2008, 129, 268-276.	3.2	7
74	T Cells in the Myenteric Plexus of Achalasia Patients Show a Skewed TCR Repertoire and React to HSV-1 Antigens. American Journal of Gastroenterology, 2008, 103, 1598-1609.	0.4	120
75	Expression and role of CCR6/CCL20 chemokine axis in pulmonary sarcoidosis. Journal of Leukocyte Biology, 2007, 82, 946-955.	3.3	43
76	The mitochondrial effects of novel apoptogenic molecules generated by psoralen photolysis as a crucial mechanism in PUVA therapy. Blood, 2007, 109, 4988-4994.	1.4	30
77	Granuloma Formation. , 2007, , 87-100.		1
78	T-cell type lymphoproliferative disease of granular lymphocytes (LDGL) is equipped with a phenotypic pattern typical of effector cytotoxic cells. Leukemia Research, 2007, 31, 371-377.	0.8	14
79	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	2.5	44
80	Circulating Progenitor Cells Are Reduced in Patients with Severe Lung Disease. Stem Cells, 2006, 24, 1806-1813.	3.2	138
81	The Promising Future of Proteomics in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1053-1054.	5.6	1
82	Epithelial CXCR3-B Regulates Chemokines Bioavailability in Normal, but Not in Sjögren's Syndrome, Salivary Glands. Journal of Immunology, 2006, 176, 2581-2589.	0.8	40
83	Modulation of Immune Response by the Acute and Chronic Exposure to High Altitude. Medicine and Science in Sports and Exercise, 2005, 37, 768-774.	0.4	75
84	Phenotypic and functional analyses of dendritic cells in patients with lymphoproliferative disease of granular lymphocytes (LDGL). Blood, 2005, 106, 3926-3931.	1.4	30
85	Role for CXCR6 and Its Ligand CXCL16 in the Pathogenesis of T-Cell Alveolitis in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1290-1298.	5.6	81
86	Arterio-venous gradient of endothelial progenitor cells across renal artery stenosis. Atherosclerosis, 2005, 182, 189-191.	0.8	13
87	Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2005, 45, 1449-1457.	2.8	671
88	CXCR3/CXCL10 interactions in the development of hypersensitivity pneumonitis. Respiratory Research, 2005, 6, 20.	3.6	26
89	CXCR3/CXCL10 expression in the synovium of children with juvenile idiopathic arthritis. Arthritis Research, 2005, 7, R241.	2.0	26
90	Relationship Between Stress Hormones And Immune Function At High Altitude. Medicine and Science in Sports and Exercise, 2005, 37, S295.	0.4	0

#	Article	IF	Citations
91	T cells in the lung of patients with hypersensitivity pneumonitis accumulate in a clonal manner. Journal of Leukocyte Biology, 2004, 75, 798-804.	3.3	15
92	New aspects of hypersensitivity pneumonitis. Current Opinion in Pulmonary Medicine, 2004, 10, 378-382.	2.6	53
93	Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood, 2004, 104, 502-508.	1.4	144
94	Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 2003, 120, 765-773.	2.5	9
95	CXCR3 and Its Ligand CXCL10 Are Expressed by Inflammatory Cells Infiltrating Lung Allografts and Mediate Chemotaxis of T Cells at Sites of Rejection. American Journal of Pathology, 2001, 158, 1703-1711.	3.8	195
96	Alveolar macrophage-T cell interactions during Th1-type sarcoid inflammation. Microscopy Research and Technique, $2001, 53, 278-287$.	2.2	35
97	Antiapoptotic Effects of IL-15 on Pulmonary Tc1 Cells of Patients with Human Immunodeficiency Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 484-489.	5.6	15
98	B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation. Cancer, 2000, 89, 1259-1268.	4.1	23
99	CXC Chemokines IP-10 and Mig Expression and Direct Migration of Pulmonary CD8 + /CXCR3 + T Cells in the Lungs of Patients with HIV Infection and T-Cell Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1466-1473.	5 . 6	95
100	Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2000, 96, 647-654.	1.4	7
101	Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L240-L250.	2.9	35
102	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells–T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	25
103	Detection of identical T-cell clonotype expansions in both the donor and recipient after allogeneic bone marrow transplantation. British Journal of Haematology, 1999, 106, 119-127.	2.5	6
104	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation, 1999, 104, 115-121.	8.2	134
105	CD8 T-Cell Infiltration in Extravascular Tissues of Patients With Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells–T-Cell Interaction. Blood, 1999, 93, 1277-1286.	1.4	11
106	Interleukin-15: A Novel Cytokine with Regulatory Properties on Normal and Neoplastic B Lymphocytes. Leukemia and Lymphoma, 1997, 27, 35-42.	1.3	39
107	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	51
108	Spontaneous resolution of p58/EB6 antigen restricted NKâ€type lymphoproliferative disease of granular lymphocytes: role of Epstein Barr virus infection. British Journal of Haematology, 1997, 99, 215-221.	2.5	14

#	Article	IF	CITATION
109	Interleukin-15 Triggers Activation and Growth of the CD8 T-Cell Pool in Extravascular Tissues of Patients With Acquired Immunodeficiency Syndrome. Blood, 1997, 90, 1115-1123.	1.4	3
110	Skewing of the T-cell receptor repertoire in the lung of patients with HIV-1 infection. Aids, 1996, 10, 729-738.	2.2	21
111	ILâ€12 is involved in the activation of CD3 + granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. British Journal of Haematology, 1996, 92, 308-314.	2.5	9
112	Lung Lymphocytes: Origin, Biological Functions, and Laboratory Techniques for Their Study in immune-Mediated Pulmonary Disorders. Critical Reviews in Clinical Laboratory Sciences, 1996, 33, 423-455.	6.1	16